• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 4. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

Recent Advances in the Application of 4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid (CAS: 890593-72-3) in Chemical Biology and Pharmaceutical Research

4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid (CAS: 890593-72-3) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. Recent studies have highlighted its role as a key intermediate in the synthesis of bioactive molecules, particularly in the design of enzyme inhibitors and receptor modulators. This research brief aims to summarize the latest findings on this compound, focusing on its chemical properties, biological activities, and potential therapeutic applications.

One of the most notable advancements in the use of 4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid is its incorporation into the synthesis of novel kinase inhibitors. Kinases are critical targets in cancer therapy, and recent research has demonstrated that derivatives of this compound exhibit potent inhibitory activity against specific kinase isoforms. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported the development of a series of pyrazole-based inhibitors, where 4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid served as a core scaffold. These inhibitors showed promising results in preclinical models of breast cancer, with enhanced selectivity and reduced off-target effects.

In addition to its role in kinase inhibition, 4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid has been explored for its potential in modulating inflammatory pathways. A recent study in Bioorganic & Medicinal Chemistry Letters investigated the anti-inflammatory properties of this compound and its derivatives. The researchers found that certain modifications to the pyrazole ring significantly enhanced the compound's ability to suppress pro-inflammatory cytokines, suggesting its potential as a lead compound for developing new anti-inflammatory drugs. This finding is particularly relevant given the growing need for therapies targeting chronic inflammatory diseases.

The chemical versatility of 4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid also extends to its use in bioconjugation and prodrug design. A 2022 study in Chemical Communications highlighted its utility as a linker in antibody-drug conjugates (ADCs), where it facilitated the stable attachment of cytotoxic payloads to monoclonal antibodies. This application underscores the compound's importance in the rapidly evolving field of targeted cancer therapies. Furthermore, its carboxylic acid functionality allows for easy derivatization, making it a valuable building block in medicinal chemistry.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of 4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid derivatives. Recent research has focused on improving their solubility and metabolic stability to enhance their therapeutic potential. For example, a 2023 study in Molecular Pharmaceutics explored the use of prodrug strategies to address these limitations, yielding derivatives with improved oral bioavailability. These efforts highlight the ongoing innovation in leveraging this compound for drug development.

In conclusion, 4-(3,5-Dimethyl-1H-pyrazol-1-yl)butanoic acid (CAS: 890593-72-3) continues to be a valuable tool in chemical biology and pharmaceutical research. Its applications in kinase inhibition, anti-inflammatory therapy, and bioconjugation demonstrate its broad utility. As research progresses, further optimization of its derivatives is expected to unlock new therapeutic opportunities, solidifying its role in the development of next-generation pharmaceuticals.

• 1015844-27-5(4-(3,5-Dimethyl-pyrazol-1-yl)-butan-1-ol)
• 890592-88-8(3-(3,5-dimethyl-1H-pyrazol-1-yl)butanoic acid)
• 180741-46-2(3-(5-Methyl-1H-pyrazol-1-yl)propanoic acid)
• 491831-88-0(1H-Pyrazole-1-butanoicacid,3,5-dimethyl-gamma-oxo-(9CI))
• 1006495-30-2(4-(3-methyl-1H-pyrazol-1-yl)butanoic acid)
• 92979-71-0(1H-Pyrazole-1-hexanoic acid, 3-carboxy-5-methyl-)
• 436086-92-9(3-(3,5-dimethyl-1H-pyrazol-1-yl)-2-methylpropanoic acid)
• 481703-72-4(5-(3,5-Dimethyl-1H-pyrazol-1-yl)-5-oxopentanoicacid)
• 1170589-47-5(ethyl 4-(3,5-dimethyl-1H-pyrazol-1-yl)butanoate)
• 72145-01-8(3-(3,5-Dimethyl-1H-pyrazol-1-yl)propanoic acid)